Degradation startup raises $39M for pivot to PROTACs and clinical entry

PAQ Therapeutics has taken a new direction. The startup shifted its protein degradation approach to the more common PROTAC lane, pivoted to cancer, hired a chief medical officer from Frontier Medicines, and secured $39 million ...